ADCs in HR+/HER2- mBC: Clinical Trial and Real-world Data

Faculty

Sara Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Statement of Need

The HR-positive/HER2-negative treatment landscape is rapidly evolving with the introduction of novel antibody-drug conjugate (ADC) therapies for patients who have developed resistance to endocrine-based therapy. This shifting paradigm effectuates uncertainty for health care practitioners regarding ADC mechanisms of action (MoAs), efficacy, safety, and value to patients.

The first episode of this CEC BriefCase series introduces a patient case that demonstrates real-world challenges faced by oncologists and their teams, provides insights into the latest developments in this therapeutic space, and discusses how to consider swiftly developing data as a key component of personalized treatment plans.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Assess the latest data from clinical trials of ADC therapies approved for the treatment of HR+/HER2-metastatic breast cancer (mBC), including safety and efficacy data and key trial design features

Financial Support

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Target Audience

Oncologists and their interprofessional team of pharmacists, nurses, nurse practitioners (NPs), and physician associates (PAs)

Credit Information

Jointly Accredited Provider

In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME)

Creative Educational Concepts, LLC, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center

This activity is designated for 0.50 contact hours.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

Accreditation Council for Pharmacy Education

This application-based activity is approved for 0.50 contact hours (0.05 CEUs) of continuing pharmacy credit (JA0007101-0000-24-005-H01-P).

American Nurses Credentialing Center with ILNA

This activity is designated for 0.50 contact hours.

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:

Disclaimer: ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

OCN®
​​☒​ Oncology Nursing Practice (Scientific Basis/Profession)
​​☒​ Treatment Modalities

AOCNP®/AOCNS®
​​☒​ Cancer Treatment

CPHON®
​​☒​ Cancer Treatment

CBCN®
​​☒​ Treatment Modalities: Local & Systemic
​​☒​ Nursing Practice (Symptom Management, EoL Care, Professional)

Physician Assistants (AAPA)

Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 07/29/2025. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education Credit for learning and change.

European Physicians (EACCME)

Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CE Concepts is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.

Disclosure Declaration

Dr. Tolaney reports the following financial relationships:

Consultant/Advisory Board (not leadership): Aadi Biosciences; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer; Blueprint Medicines Corporation; Bristol Myers Squibb Company; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; eFFECTOR;  Eisai Inc.; Eli Lilly and Company; Genentech, Inc./Roche; Gilead Sciences, Inc.; Hengrui USA; Incyte; Infinity Therapeutics; Jazz Pharmaceuticals, Inc.; Menarini/Stemline Therapeutics, Inc.; Merck & Co., Inc.; Natera, Inc.; Novartis Pharmaceuticals Corporation; OncXerna Therapeutics, Inc.; Pfizer Inc.; Reveal Genomics; Sanofi; Seattle Genetics; Inc.; Sumitovant Biopharma, Inc.; SystImmune, Inc.; Tango Therapeutics; Umoja Biopharma; Zentalis Pharmaceuticals; and Zymeworks Inc.

Research Support (paid to institution): AstraZeneca; Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./Roche; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; Pfizer Inc.; and Seattle Genetics, Inc.

Other financial or material support (travel support): Eli Lilly and Company; Sanofi; Gilead Sciences, Inc.; and Jazz Pharmaceuticals, Inc.

The following individuals have no financial relationships to disclose: 

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Katherine E. Lee, PharmD, MPH (Planning Committee)
Nichole Lainhart (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.

Questions about this activity?

Call us at 859-260-1717  •  info@ceconcepts.com

BC-119-072924-47

Call us at 859-260-1717  •  info@ceconcepts.com

ADCs in HR+/HER2- mBC: Clinical Trial and Real-world Data
Activity Date: 07/23/2024